Trial Profile
Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2019
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin
- Indications Coronary arteriosclerosis; Coronary thrombosis
- Focus Adverse reactions
- 13 Mar 2019 Results published in the American Heart Journal
- 13 Jul 2017 Trial design published in the Clinical Cardiology
- 27 Apr 2017 Status changed from active, no longer recruiting to completed.